00043: THE NEW FRENCH TROPHOBLASTIC DISEASE REFERENCE CENTER: 5-YEAR RESULTS

From November 1999 to November 2004, 448 patients were registered to the French Trophoblastic Disease Reference Center in Lyon, France. 333 patients with molar pregnancies were registered. 212 had complete hydatidiform moles (CHM), 108 had partial moles (PHM), 9 had twin pregnancies with partial or complete mole and 4 had undefined pathological type of molar pregnancy. 37 of them (11 %) further developed a gestational trophoblastic neoplasia. 134 patients with gestational trophoblastic neoplasia (GTN) were registered. 2000 FIGO diagnostic criteria for GTN were used. The antecedent pregnancy was a mole in 105 out of 134 GTN (78 %). 3 patients had a placental site trophoblastic tumor (PSTT). According to 2000 FIGO scoring system (therefore excluding 3 PSTT), 115 in 131 patients (88 %) had low risk GTN (FIGO score = 6). When the antecedent pregnancy was a mole, the interval from evacuation to initiation of treatment was less than 4 months in 81 % of cases. Methotrexate day 1, 3, 5, 7 every 14 days was the usual chemotherapy schedule for low risk patients while most high risk patients were treated with the classical EMA-CO regimen. Our 5-year results with 448 trophoblastic disease patients underscore the need for reference centers to improve the quality of care to patients. 2000 FIGO scoring system is an excellent way to allow comparison of results and European countries involved in trophoblastic disease should gather their experience to create a supranational database for this rare disease.